Cooperative Agreement UG3DA066252
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $2.8M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $2.175 million on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized controlled clinical trial evaluating non-abstinence treatment outcomes for methamphetamine use disorder. The trial will enroll 200 treatment-seeking individuals with methamphetamine use disorder and randomly assign them to two groups: one receiving financial incentives...
- The National Institute on Drug Abuse awarded the University of Oklahoma Health Sciences Center $116,664 on January 6, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support basic research examining neurotensin's effects on ventral tegmental area neuron physiology and methamphetamine use disorder. The research uses patch clamp electrophysiology and behavioral assessment techniques to investigate how neurotensin modulates reward behavior through its receptors NTR1 and...
- The National Institute on Drug Abuse awarded Clear Scientific, LLC a $3 million cooperative agreement on August 1, 2026, to conduct a Phase 2A clinical study evaluating the safety and efficacy of CS-1103, a therapeutic agent to treat methamphetamine intoxication, under the Drug Use and Addiction Research Programs (CFDA 93.279). CS-1103 operates through dual mechanisms: rapid reversal of acute methamphetamine toxidrome symptoms and acceleration of methamphetamine clearance from the body by...
- The National Institute on Drug Abuse awarded Oklahoma Medical Research Foundation $648,389 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate cell type-specific neurotensin signaling in methamphetamine use disorder. The research combines intravenous methamphetamine self-administration in genetically-modified mice, brain slice electrophysiology, and virus-induced expression of designer ligand-sensitive proteins to determine how neurotensin...
- The National Institute on Drug Abuse awarded a $6.239 million Cooperative Agreement to the University of Texas Health Science Center at Houston on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds development and evaluation of a novel treatment combining contingency management behavioral therapy with deep transcranial magnetic stimulation (H4 coil) to improve outcomes in treatment-resistant cocaine use disorder. The study employs a two-stage...
- The National Institute on Drug Abuse, a component of the Department of Health and Human Services, awarded the University of Utah $201,960 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a mixed-methods feasibility trial of transcranial magnetic stimulation (TMS) as a therapeutic intervention for methamphetamine use disorder during pregnancy. The award funds a clinician-investigator training and research project spanning five years through June 30,...
- The National Institute on Drug Abuse awarded Wake Forest University Health Sciences $100,228 on November 7, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research investigating the role of synaptogyrin-3 in methamphetamine self-administration and dopamine dysfunction. The project examines synaptogyrin-3, a synaptic vesicle protein hypothesized to regulate dopamine release and uptake in the brain's reward circuitry. The research tests whether viral...
- The National Institute on Drug Abuse awarded the University of Utah $423,500 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test a remote collaborative care-facilitated contingency management program integrated with cardiac rehabilitation for individuals with methamphetamine-associated congestive heart failure and methamphetamine-associated pulmonary arterial hypertension. The project addresses the growing prevalence of cardiopulmonary...
- The National Institute on Drug Abuse awarded the University of California, San Diego $4.951 million on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Brain-Focused Research on Antiretrovirals and Methamphetamine (BRAIN-FRAME) project through March 31, 2031. The award funds research examining how long-acting injectable antiretroviral therapy (LAI-ART) and medication-assisted treatment (MAT), including LAI naltrexone, interact to improve brain...
- The National Institute on Drug Abuse, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Utah $462,000 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop photochemical tools for investigating neuropeptide modulation during methamphetamine withdrawal. The project will engineer a modular library of cyclic, photolabile caging scaffolds that render corticotropin releasing factor (CRF),...